BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In light of the crucial role of the BCR-ABL tyrosine kinase in chronic myelogenous leukemia, TKIs have become the first-line therapy for most patients with chronic myelogenous leukemia [4], [32],[33].